Aspirin/omeprazole 650/20

Drug Profile

Aspirin/omeprazole 650/20

Alternative Names: Aspirin/omeprazole 650mg/20mg; OA-65020; Omeprazole/aspirin 20/650; PA-65020

Latest Information Update: 22 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 07 Dec 2012 Phase-I development is ongoing in USA
  • 01 Oct 2012 Aspirin/omeprazole 650/20 is available for licensing as of 01 Oct 2012.
  • 03 Nov 2010 POZEN receives Qualifying Therapeutic Discovery Project grant from the Department of Health and Human Services in the US under the Patient Protection and Affordable Care Act of 2010 (PPACA) for aspirin/omeprazole development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top